Evidence map›Paper›PMID 39818516›Full record

ArticleClinical lung cancer2025

Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.

Michael T Marrone, Joshua E Reuss, Anna Crawford, Brian Neelon, Jun O Liu, Julie R Brahmer, Elizabeth A Platz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael T MarroneDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. Electronic address: marronmi@musc.edu.
Joshua E ReussDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Anna CrawfordHollings Cancer Center Biostatistics Shared Resource, Medical University of South Carolina, Charleston, SC.
Brian NeelonDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC; Hollings Cancer Center Biostatistics Shared Resource, Medical University of South Carolina, Charleston, SC.
Jun O LiuDepartment of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD.
Julie R BrahmerDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
Treg functional changes: a novel immune regulatory effect underlying the benefit of statin drug use on lethal prostate cancerR00CA246097 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARRONE, MICHAEL THOMAS · 2022 to 2025
$723k
NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA138313NCI NIH HHS R00 CA246097
6 · The paper itself

Abstract

objectiveTo determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC). MATERIALS AND

methodsSEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first. Associations for time-updated statin use and lung cancer-specific mortality, and overall mortality were estimated using Cox models adjusted for demographic, pathological, treatment-related factors, and a propensity score for statin use.

resultsAmong 1,401 patients, concurrent statin use with any ICI was associated with 41% lower risk of lung-cancer specific mortality compared to patients receiving ICI not using a statin (HR = 0.59; 95% CI = 0.35-0.99). Statin use was associated with a similarly lower risk of overall mortality (HR = 0.62; 95% CI = 0.41-0.94). Consistent inverse associations were observed when restricting to PD-1 inhibitors and by statin type. Limited anti-PD-L1 treatment prevented analysis in this subgroup.

conclusionConcurrent statin use with ICIs was associated with lower risk of lung cancer-specific and overall mortality in a population-based sample of older patients with NSCLC. Future work is needed to confirm these findings in prospective studies and randomized trials, including evaluating concurrent statin use with frontline ICIs, deciphering the underlying mechanism, and determining the optimal statin-ICI combination that maximize clinical benefit.

Indexed as

Carcinoma, Non-Small-Cell LungHydroxymethylglutaryl-CoA Reductase InhibitorsImmune Checkpoint InhibitorsLung NeoplasmsAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMedicareRetrospective StudiesSEER ProgramSurvival RateUnited StatesHydroxymethylglutaryl-CoA Reductase InhibitorsImmune Checkpoint InhibitorsMortalityOlder adultsRetrospective cohort studySEER-MedicareSurvival analysis

Identifiers

PMID39818516
PMCPMC12037305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.